Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients

Launched by UNIVERSITY HOSPITAL OSTRAVA · Jul 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to predict kidney problems in patients with high blood pressure (arterial hypertension). It looks at a substance called Fetuin A found in urine, which may help doctors identify kidney deterioration earlier than traditional tests. Currently, the usual tests, like measuring creatinine levels or checking urine for protein, tend to show issues only when kidney damage is already advanced. By focusing on urine Fetuin A, researchers hope to find a more effective method for monitoring kidney health in people with high blood pressure.

To participate in this trial, you should be between 65 and 75 years old and currently taking at least one medication for high blood pressure. However, you cannot have diabetes or severe high blood pressure that is not well controlled. Additionally, certain other health conditions, like serious liver disease or autoimmune disorders, may prevent you from participating. If you decide to join, you can expect regular check-ups and tests to help researchers understand how urine Fetuin A relates to kidney function over time. This study is currently looking for participants, so it could be a chance to contribute to important research that may improve kidney health monitoring in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Arterial hypertension treated by at least one antihypertensive agent
• Exclusion Criteria:
• • Diabetes mellitus of any type, defined as fasting glucose \>7,0 mmol/l or any glycemia \>11,0 mmol/l, or HbA1c\>48 mmol/mol
• • Decompensated arterial hypertension defined as office blood pressure \>180/110 mmHg or on Ambulatory Blood Pressure Monitoring (ABPM)
• • Patient with renal replacement therapy
• • Present rheumatoid disease (rheumatoid arthritis, systemic lupus, sclerodermia, dermatomyositis, Inflammatory Bowel Disease, etc.), positivity of antinuclear antibody (ANA) / extractable nuclear antigen (ENA) screening
• • Acute infection defined as C-Reactive Protein (CRP) \>50 mg/l
• • Severe impairment of liver function defined as cirrhosis, Alanine Transaminase or ASpartate Transferase (ALT or AST) \>10 µkat/l
• • Terminal incurable illness